Acrivastine: Difference between revisions
No edit summary |
Kiran Singh (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name | | Verifiedfields = changed | ||
| image | | verifiedrevid = 477241254 | ||
| IUPAC_name = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl-<br>prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | |||
| image =Acrivastine.png | |||
{{ | <!--Clinical data--> | ||
| tradename = | |||
| Drugs.com = {{drugs.com|international|acrivastine}} | |||
| MedlinePlus = a682619 | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = B | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | |||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | |||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | |||
| legal_US = Rx-only | |||
| routes_of_administration = oral | |||
<!--Pharmacokinetic data--> | |||
| elimination_half-life = 1.5 hours | |||
| excretion = [[Kidney|Renal]] | |||
== | <!--Identifiers--> | ||
| CAS_number_Ref = {{cascite|changed|??}} | |||
| CAS_number = 87848-99-5 | |||
| ATC_prefix = R06 | |||
| ATC_suffix = AX18 | |||
| PubChem = 5284514 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 4447574 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = A20F9XAI7W | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D02760 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 1224 | |||
| ChEBI_Ref = {{ebicite|changed|EBI}} | |||
| ChEBI = 83168 | |||
<!--Chemical data--> | |||
| C=22 | H=24 | N=2 | O=2 | |||
| molecular_weight = 348.438 g/mol | |||
| smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | |||
| InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | |||
| InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N | |||
}} | |||
'''Acrivastine''' is a medication used for the treatment of allergies and [[hay fever]]. It is a second-generation [[H1 antagonist|H1-receptor antagonist]] [[antihistamine]] (like its base molecule [[triprolidine]]) and works by blocking [[Histamine H1 receptor]]s. | |||
This non-sedating{{verify source|date=November 2014}} antihistamine is sold under the brand name Benadryl Allergy Relief in the [[United Kingdom]] by [[McNeil Laboratories]], not to be confused with Benadryl Once a Day, which is [[cetirizine]] and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand | |||
In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a [[decongestant]], [[pseudoephedrine]]. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.<ref>[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7627 SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule] U.S. [[National Library of Medicine]], National Institutes of Health, May 2008</ref> | |||
==Comparisons with other popular antihistamines== | |||
Unlike [[cetirizine]] or [[loratadine]], the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.<ref>{{cite web |url=http://www.medicines.org.uk/EMC/pdfviewer.aspx?isAttachment=true&documentid=21852 |title=Benadryl Allergy Relief |work=electronic Medicines Compendium (eMC) |year=2014 |accessdate=4 July 2014}}</ref> Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function. | |||
==References== | ==References== | ||
{{reflist|2}} | |||
{{Antihistamines}} | {{Antihistamines}} | ||
{{Histaminergics}} | |||
[[Category:H1 receptor antagonists]] | [[Category:H1 receptor antagonists]] | ||
[[Category: | [[Category:Pyridines]] | ||
[[Category:Pyrrolidines]] | |||
[[ | [[Category:Alkenes]] | ||
[[ | [[Category:Drug]] | ||
Revision as of 18:38, 10 April 2015
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477241254
| IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
| image =Acrivastine.png
| tradename = | Drugs.com = International Drug Names | MedlinePlus = a682619 | pregnancy_AU = | pregnancy_US = B | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = oral
| elimination_half-life = 1.5 hours | excretion = Renal
| CAS_number_Ref = | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank_Ref = | ChemSpiderID_Ref = | ChemSpiderID = 4447574 | UNII_Ref = | UNII = A20F9XAI7W | KEGG_Ref = | KEGG = D02760 | ChEMBL_Ref = | ChEMBL = 1224 | ChEBI_Ref = | ChEBI = 83168
| C=22 | H=24 | N=2 | O=2 | molecular_weight = 348.438 g/mol | smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | StdInChI_Ref = | StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | StdInChIKey_Ref = | StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N }} Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.
This non-sedating[verification needed] antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand
In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a decongestant, pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]
Comparisons with other popular antihistamines
Unlike cetirizine or loratadine, the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.[2] Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.
References
- ↑ SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
- ↑ "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- Articles with changed EBI identifier
- All pages needing factual verification
- Wikipedia articles needing factual verification from November 2014
- Articles with invalid date parameter in template
- H1 receptor antagonists
- Pyridines
- Pyrrolidines
- Alkenes
- Drug